PMID: 8690825Apr 1, 1996Paper

Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo

Journal of Clinical Psychopharmacology
L L von MoltkeR I Shader

Abstract

Biotransformation of the H-1 antagonist terfenadine to its desalkyl and hydroxy metabolites was studied in vitro using microsomal preparations of human liver. These metabolic reactions are presumed to be mediated by Cytochrome P450-3A isoforms. The azole antifungal agent ketoconazole was a highly potent inhibitor of both reactions, having mean inhibition constants (Ki) of 0.037 and 0.34 microM for desalkyl- and hydroxy-terfenadine formation, respectively. Itraconazole also was a potent inhibitor, with Ki values of 0.28 and 2.05 microM, respectively. Fluconazole, on the other hand, was a weak inhibitor. Six selective serotonin reuptake inhibitor antidepressants tested in this system were at least 20 times less potent inhibitors of terfenadine metabolism than was ketoconazole. An in vitro-in vivo scaling model used in vitro Ki values, typical clinically relevant plasma concentrations of inhibitors, and presumed liver:plasma partition ratios to predict the degree of terfenadine clearance impairment during coadministration of terfenadine with these inhibitors in humans. The model predicted a large and potentially hazardous impairment of terfenadine clearance by ketoconazole and, to a slightly lesser extent, by itraconazole. However...Continue Reading

References

Jan 6, 1992·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·M MauriceP Maurel
Nov 1, 1992·Clinical Pharmacology and Therapeutics·D J GreenblattJ S Harmatz
Nov 1, 1992·The Journal of Clinical Investigation·J C KolarsP B Watkins
Jan 1, 1991·European Journal of Clinical Pharmacology·M P Gascon, P Dayer
Jan 1, 1991·Journal of Pharmaceutical and Biomedical Analysis·T M ChenR A Okerholm
Apr 1, 1988·Clinical Pharmacology and Therapeutics·L LembergerR F Bergstrom
Jul 1, 1987·Journal of Analytical Toxicology·A D FraserR A Perry
Jan 1, 1984·Journal of Analytical Toxicology·R J Wong
Dec 1, 1983·Journal of Pharmacokinetics and Biopharmaceutics·Y IgariM Hanano
Jan 1, 1981·Biochemical Pharmacology·T Spector, W W Cleland
Jul 1, 1995·Clinical Pharmacology and Therapeutics·D Y GomezL Z Benet
Dec 1, 1994·Journal of Clinical Pharmacology·L L von MoltkeR I Shader
Oct 1, 1994·Pharmacogenetics·J C KolarsP B Watkins
Jul 1, 1994·Clinical Pharmacokinetics·K T KivistöU Klotz
Nov 1, 1994·Clinical Pharmacology and Therapeutics·E PeruccaM Bialer
Aug 1, 1994·British Journal of Clinical Pharmacology·T AnderssonD J Birkett
Sep 1, 1994·Journal of Analytical Toxicology·B LevineJ E Smialek
Jan 1, 1994·European Journal of Clinical Pharmacology·J C Fleishaker, L K Hulst
Nov 1, 1993·The Annals of Pharmacotherapy·M P Swims
Mar 1, 1993·Clinical Pharmacokinetics·J van Harten
Mar 24, 1993·JAMA : the Journal of the American Medical Association·P K HonigL R Cantilena
Sep 1, 1995·The Annals of Pharmacotherapy·R J MarchiandoS G Jue
Dec 1, 1995·Journal of Clinical Psychopharmacology·D S GreeneR H Barbhaiya
Oct 1, 1995·Journal of Clinical Psychopharmacology·P D KrobothD E Salazar
Oct 1, 1995·Journal of Clinical Psychopharmacology·R H BarbhaiyaD S Greene

❮ Previous
Next ❯

Citations

Feb 22, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Siamak Cyrus KhojastehAnthony Y H Lu
Dec 4, 1998·Biological Psychiatry·S RotzingerG B Baker
May 14, 1998·Neuroscience and Biobehavioral Reviews·G B BakerR T Coutts
Jul 30, 1999·Journal of the American Academy of Dermatology·A K GuptaN H Shear
Mar 30, 2002·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Larry C Wienkers
Jun 1, 1996·Journal of Clinical Psychopharmacology·R I ShaderD J Greenblatt
Dec 31, 1997·Journal of Clinical Psychopharmacology·D E MartinD K Jorkasky
Jan 25, 2003·Journal of Clinical Psychopharmacology·Harry J WitchelDavid J Nutt
May 27, 2006·Journal of Psychiatric Practice·Sheldon H Preskorn
May 1, 2004·Journal of Clinical Psychopharmacology·Gonzalo CalvoManel Barbanoj
Oct 6, 2005·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Toshiro NiwaAkira Takagi
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
Aug 12, 2003·Clinical Pharmacokinetics·Megan A Gibbs, Natilie A Hosea
Aug 12, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·A G Renwick
Jan 7, 1998·Clinical Therapeutics·P E Stokes, A Holtz
Mar 6, 2012·Expert Opinion on Drug Metabolism & Toxicology·Justin D Lutz, Nina Isoherranen
Oct 21, 2005·British Journal of Clinical Pharmacology·Kerry E Culm-MerdekDavid J Greenblatt
Jan 6, 2004·Fundamental & Clinical Pharmacology·Edoardo SpinaConcetta D'Arrigo
Feb 4, 1998·Biochemical Pharmacology·L L von MoltkeR I Shader
Jun 1, 1997·Home Care Provider·L Ashworth
Oct 3, 1998·Clinical Pharmacology and Therapeutics·A D KashubaJ S Bertino
Feb 2, 2006·The Journal of Antimicrobial Chemotherapy·C CharlierO Lortholary
Feb 24, 1998·Journal of Clinical Psychopharmacology·J S MarkowitzC L DeVane
Apr 11, 2001·Therapeutic Drug Monitoring·J LundmarkF Bengtsson
Oct 8, 1998·The Annals of Pharmacotherapy·B M Lomaestro, M A Piatek
Aug 18, 2010·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·David J GreenblattLisa L von Moltke
Feb 25, 2009·Clinical Pharmacology and Therapeutics·A LiukasK T Olkkola
Oct 24, 2017·British Journal of Clinical Pharmacology·Florine A BergerPatricia M L A van den Bemt
Jul 15, 2000·British Journal of Clinical Pharmacology·M Jurima-RometS Neigh
May 9, 2002·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Zhao-Qian LiuHong-Hao Zhou
Apr 5, 2002·Biopharmaceutics & Drug Disposition·Byoung C KangWan G Shin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Landau-Kleffner Syndrome

Landau Kleffner syndrome (LKS), also called infantile acquired aphasia, acquired epileptic aphasia, or aphasia with convulsive disorder, is a rare childhood neurological syndrome characterized by the sudden or gradual development of aphasia (the inability to understand or express language) and an abnormal electroencephalogram. Discover the latest research on LKS here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.